About Draig Therapeutics
Draig Therapeutics develops therapies for neuropsychiatric disorders. The company creates neuromodulators designed to regulate neurotransmission pathways. Its pipeline includes DT-101 for major depressive disorder and other modulators for additional neuropsychiatric indications. Draig advances these programs through preclinical and clinical development for patients.
Company Details
Corporate & Operational Profile
Web & Domain Identity
Social & Network Presence
Company Milestones & Timeline
- Capital Raise
Raised $65,000,000 · Series-B+
fundraisingfox.com
- Capital Raise
Raised $140,000,000 · Seed
- Milestone
Website domain registered
draigtherapeutics.com
Investors & Backers
Funding History
Founders & Leadership
Florian Islinger
Chief Commercial Strategy Officer
Inderjit Kaul
Chief Medical Officer
Ivana Magovčević-Liebisch
President and Chief Executive Officer
John Atack
Head of Biology & Founder
Ruth McKernan
Founder
Simon Ward
Chief Scientific Officer & Founder
Weeteck Yeo
SVP, Business Operations & Chief of Staff
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Hexagon Bio
hexagonbio.com
RefloDx
reflodx.com
HeyVoli
heyvoli.com
CureBay
curebay.com
4Tissue
4tissue.com